STunning in Acute Myocardial Infarction - BAS
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
Vastra Gotaland Region
120 participants
Jan 6, 2025
INTERVENTIONAL
Conditions
Summary
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
Eligibility
Inclusion Criteria2
- Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)
- Informed consent
Exclusion Criteria7
- Killip class ≥ 3
- Chronic kidney disease with GFR < 25 ml/min/1.73 m2
- Pre-existing non-reversible cardiac dysfunction or heart failure
- Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor
- Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician
- Life expectancy less than one year
- Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Timing of drug intervention after PCI
Timing of drug intervention after PCI
Timing of drug intervention after PCI
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06562582